Table 3.
R2 | Beta | t | 95% Confidence intervals |
sig | ||
---|---|---|---|---|---|---|
lower | upper | |||||
0.21 | ||||||
MDS-UPDRS-III | 0.003 | 0.185 | −0.031 | 0.038 | 0.853 | |
MDS-UPDRS-IV | 0.213 | 2.121 | 0.016 | 0.411 | 0.034 | |
SCOPA | 0.224 | 6.031 | 0.151 | 0.297 | < 0.001 | |
LADS | 0.224 | 5.347 | 0.142 | 0.307 | < 0.001 | |
MoCA | −0.005 | −0.076 | −0.135 | 0.125 | 0.940 | |
Age | −0.072 | −2.801 | −0.123 | −0.022 | 0.005 | |
Disease Duration | 0.071 | 0.676 | −0.136 | 0.278 | 0.394 | |
Gender (Female) | 1.619 | 3.450 | 0.698 | 2.540 | 0.001 |
MDS-UPDRS-III, Unified Parkinson's disease Rating Scale Part III (motor examination); MDS-UPDRS-IV, Unified Parkinson's disease Rating Scale Part IV (motor complications); SCOPA-AUT, the Scales for Outcomes in Parkinson's disease – Autonomic Symptoms; LADS, Leeds Anxiety and Depression Scale; MoCA, Montreal Cognitive Assessment.